Most newly discharged sufferers who recently recovered from COVID-19 produce virus-specific antibodies, and T cells suggests a study featured on May 3rd in the journal Immunity, but the responses of various sufferers are not all identical.
Whereas the 14 patients examined in the research showed wide-ranging immune responses, outcomes from the 6 of them that have been assessed at two weeks after discharge suggest that antibodies were maintained for a minimum of that long.
Additional results from the examine point out which elements of the virus are at triggering these immune responses and may, therefore, be targeted by potential vaccines.
It isn’t clear why immune responses varied extensively across the sufferers. The authors say this variability may be associated with the initial quantities of virus that the sufferers encountered, their physical states, or their microbiota.
Other open questions embody whether these immune responses defend against COVID-19 upon re-exposure to SARS-CoV-2, in addition to which types of T cells are activated by infection with the virus. It is usually vital to note that the laboratory assessments that are used to detect antibodies to SARS-CoV-2 in humans nonetheless want additional validation to find out their accuracy and reliability.
Relatively little is known in regards to the protective immune responses induced by the disease-causing virus, SARS-CoV-2, and addressing this hole in data may speed up the development of an effective vaccine, provides co-senior study author Cheng-Feng Qin of the Academy of Military Medical Sciences in Beijing.